Clearmind Medicine Secures $2.43M in Highly Dilutive Convertible Note Financing
CMND sits 79% above its 52-week low of $0.586 on elevated volume (51× avg).
Summary
Clearmind Medicine Inc. announced it will issue $2.7 million in convertible promissory notes for $2.43 million in cash, a financing event that represents over 100% of its current market capitalization.
Key Events · Financing and Capital Events · CMND
-
New Convertible Note Issuance
Clearmind Medicine will issue convertible promissory notes with an aggregate principal amount of $2,700,000 to CLA Investors.
-
Cash Proceeds
The company will receive $2,430,000 in cash, representing 90% of the principal amount of the notes, with the transaction expected to close around April 21, 2026.
-
Highly Dilutive Financing
This capital raise is equivalent to over 100% of the company's current market capitalization, indicating significant potential dilution for existing shareholders upon conversion.
-
Continuation of Prior Program
This issuance is part of a previously announced program from September 2025 to issue up to $10,000,000 in convertible promissory notes from time to time.
Analysis · CMND · Life Sciences
This significant capital raise provides Clearmind Medicine with crucial funding, especially following recent positive clinical trial news for CMND-100. However, the issuance of convertible promissory notes, purchased at a 10% discount to their principal amount, implies substantial future dilution for existing shareholders. This transaction, which is larger than the company's entire market capitalization, continues a pattern of dilutive financing seen in recent days and will significantly impact the company's share structure and valuation. Investors should monitor the conversion terms and potential impact on per-share metrics.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.59 to $52.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.